Single-Site vs. Multiple-Site Bone Marrow Harvesting: Which Method Minimizes Pain and Delivers Quality?
"A new study investigates if single-site bone marrow aspiration, with needle redirection, offers a less painful yet equally effective alternative to multi-site harvesting for regenerative treatments."
Bone marrow concentrate (BMC) is increasingly used as a promising alternative treatment in orthopedics, particularly for its regenerative properties. The effectiveness of BMC is closely linked to the number of mesenchymal stem cells (MSCs) present in the graft. Harvesting techniques significantly affect MSC counts in bone marrow aspirate (BMA).
The crucial question remains: Which aspiration method optimizes cellular yield while ensuring patient comfort and minimizing risks? Balancing these factors is essential for a safe and effective aspiration technique that can maximize the therapeutic potential of BMC.
A controlled laboratory and cohort study was conducted to compare single- versus multiple-site bone marrow aspiration techniques. The primary goal was to determine which method generates a sufficient volume of high-quality BMA for concentration into a BMC graft, all while monitoring the level of pain experienced by the patient.
Current Evidence and Clinical Impact
Bone marrow aspirate concentrate (BMAC) is being studied as a treatment for knee osteoarthritis because it contains mesenchymal stem cells and may help attenuate inflammatory pathways. A prospective study investigated the mid-term outcomes of BMAC injections in patients with severe knee osteoarthritis. Another retrospective study examined 160 knee osteoarthritis patients treated with bone marrow aspirate obtained using a novel MC aspiration technique, measuring pain reduction with the visual analog scale six months after treatment. However, available aspiration and concentration methods remain varied, and further data are needed to identify the optimal harvesting techniques.
Methods and Standardization Challenges
Bone marrow harvesting and BMAC treatment do not follow one uniformly established protocol. Comparative studies have reported variability in procedure protocols, limiting the ability to draw meaningful conclusions across studies. Differences also occur in BMAC preparation methods, injection protocols, and patient-selection criteria. A 2026 study specifically compares traditional aspiration with the Snap Back technique at the posterior iliac crest and proximal tibia, underscoring that both technique and anatomical harvest site remain active areas of investigation.
From Marrow Biology to BMAC
Human bone marrow became important to regenerative medicine because it contains mesenchymal stem cells, growth factors, and cytokines that may support anti-inflammatory and regenerative processes in cartilage and bone. Later research increasingly examined bone marrow aspirate concentrate for knee osteoarthritis. A 2024 systematic review updated the literature on patient selection, BMAC preparation, and efficacy compared with other biological alternatives. This progression reflects a shift from foundational marrow biology toward evaluating practical clinical applications.
Single-Site Aspiration: Less Pain, Same Quality?
In this study, researchers compared two bone marrow harvesting methods: a single-site technique with needle redirection and a multiple-site technique. Six participants underwent bilateral bone marrow aspiration, with each technique performed on opposite sides of the posterior iliac crest. BMA and BMC samples were analyzed for various cellular components, including white blood cells, total nucleated cells, and MSCs. Pain scores were monitored during and after the procedure.
- Comparable Cell Yields: Both single-site and multiple-site techniques yielded similar cell ratios and colony-forming units.
- MSC Numbers: No significant difference in mesenchymal stem cell counts between the two methods.
What Recent Reviews Show
Recent reviews describe BMAC as an autologous therapy enriched with mesenchymal stem cells and bioactive growth factors, with potential disease-modifying effects in knee osteoarthritis. At the same time, evidence confirming unequivocal efficacy remains limited. The literature continues to address ideal patient selection, preparation methods, and comparisons with other biological treatments. These reviews therefore support continued investigation rather than a definitive conclusion that BMAC is effective for every patient.
Where Evidence Remains Uncertain
BMAC should not be presented as a guaranteed solution for knee osteoarthritis. Outcomes may be difficult to interpret when harvesting, processing, injection, and patient-selection methods differ between studies. The available evidence may indicate potential benefit, but uncertainty about the optimal protocol and the consistency of results remains a significant limitation.
Comparing Cell-Based Options
One study compared a single BMAC injection with a cycle of four autologous conditioned serum injections for early-stage knee osteoarthritis. A separate systematic review and meta-analysis examined BMAC alongside stromal vascular fraction as cell-based treatment options. Both source descriptions emphasize that clinical evidence comparing these therapies remains limited. Comparisons therefore provide useful context but do not yet establish a clearly superior cell-based treatment.
The Bottom Line: Prioritizing Patient Comfort in Bone Marrow Harvesting
This study highlights that a single-insertion method can produce final cellular concentrations and culture results comparable to a multiple-insertion method. Crucially, the single-insertion site technique significantly reduces pain during and after the procedure.
A Cautious Evidence-Based View
Systematic reviews have evaluated isolated BMAC injection as a treatment for symptomatic knee osteoarthritis. Their purpose has been to assess efficacy across the available literature rather than to assume that the treatment works uniformly. The evidence supports BMAC as a therapeutic option under investigation, but it does not remove the need to consider study quality, patient selection, and procedural variation. Expert interpretation should therefore distinguish potential clinical value from definitive proof of effectiveness.
The Next Research Questions
Future research will need to clarify which harvesting and processing approaches provide the best balance of tolerability and treatment quality. More consistent protocols could make results easier to compare across studies. Research should also continue evaluating which patients are most likely to benefit and how BMAC compares with other biological treatments. Until those questions are answered, the field remains promising but not fully settled.
The Challenge of Comparing Treatments
A systematic review reported that intra-articular BMAC has shown effectiveness in clinical trials by improving functional outcomes in patients with knee osteoarthritis. However, the superiority of BMAC over other orthobiological treatments could not be assessed because study results were conflicting. This uncertainty reflects a broader challenge in comparing regenerative treatments across different protocols and patient groups. BMAC may therefore be clinically useful without being demonstrably superior to every alternative.
Mobility, Pain, and Patient Experience
Clinical studies have evaluated single intra-articular BMAC injections for both efficacy and safety in people with knee osteoarthritis. One 2020 study assessed early outcomes using a novel closed-end, fenestrated trocar that did not require centrifugation. A Mayo Clinic case report described a patient whose osteoarthritis pain began affecting her left knee and threatened her mobility; before later treatment described in the report, she had received two PRP injections in January 2015. These reports illustrate why patients may pursue marrow-based or related biologic treatments when pain begins to restrict daily activity and an active lifestyle.
For patients undergoing bone marrow aspiration, this research suggests that a single-stick approach is a viable option that minimizes discomfort without compromising the quality of the aspirate.
As regenerative medicine continues to evolve, prioritizing patient comfort alongside clinical efficacy will drive the adoption of less invasive yet equally effective techniques in bone marrow harvesting.